Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Beclometasone dipropionate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR……… Easyhaler Beclometasone is packed in an inhaler called Easyhaler. Beclometasone dipropionate belongs to a group of medicines called corticosteroids (often just called steroids). A very small dose of steroid is needed when it is inhaled. This is because it is inhaled straight to your lungs. Easyhaler Beclometasone works by reducing swelling and irritation in the lungs. They have what is called an 'anti-inflammatory action'. Easyhaler Beclometasone helps to prevent asthma in people who need regular treatment. This is why they are sometimes called 'preventers'. They need to be used regularly, every day. Easyhaler Beclometasone will not help treat sudden asthma attacks where you feel breathless.
E EASYHALER BECLOMETASONE Do not use Easyhaler Beclometasone if you are allergic (hypersensitive) to: • beclometasone dipropionate • lactose (which contains small amount of milk proteins) • any of the other ingredients of Easyhaler Beclometasone (listed in Section 6). 1
Do not use Easyhaler Beclometasone if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before using Easyhaler® Beclometasone. Warnings and precautions Talk to your doctor, nurse or pharmacist before using Easyhaler Beclometasone: • if you have ever been treated for tuberculosis (TB) • if you are using Easyhaler Beclometasone at the same time as taking steroid tablets. Also if you have just finished taking steroid tablets. In both cases, you should carry a steroid warning card until your doctor tells you not to carry one. Contact your doctor if you experience blurred vision or other visual disturbances. If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before using Easyhaler Beclometasone. Children Easyhaler Beclometasone is not recommended for use in children Other medicines and Easyhaler Beclometasone
Easyhaler Beclometasone is not recommended for use in children. If you are using high doses of an inhaled steroid for a long time you may sometimes need extra steroids for example during stressful circumstances such as a road traffic accident or before an operation. Your doctor may decide to give you extra steroid medicines during this time. If you use more Easyhaler Beclometasone than you should If you use more than you should, talk to your doctor as soon as possible. It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. If you forget to use Easyhaler Beclometasone
CORRECTLY Step 1: SHAKE
SHAKE x 3-5
Important points to remember
6
Step 2: CLICK
CLICK x 1
Important points to remember
Step 3: INHALE
Important points to remember
If you need to take another inhalation, please repeat the steps 1-3 Shake-Click-Inhale. After you have used the inhaler:
7
How to empty the powder from the mouthpiece If you click the inhaler by accident, or if you might have clicked it more than once, or if you breathe out into it, empty the mouthpiece.
Cleaning the Easyhaler Keep your inhaler dry and clean. If necessary you may wipe the mouthpiece of your inhaler with a dry cloth or tissue. Do not use water: the powder in the Easyhaler is sensitive to moisture. Using the Easyhaler with a protective cover You may use a protective cover with your inhaler.This helps to improve durability of the product. When you first insert your inhaler in the protective cover make sure the dustcap is on the inhaler as this stops it going off by accident. You can use the inhaler without removing it from the protective cover. Follow the same instructions as above, 1. Shake – 2. Click – 3. Inhale. Remember to:
inhaler going off by accident.
When to switch to a new Easyhaler The dose counter shows the number of remaining doses. The counter turns after every 5th click. When the dose counter starts turning red, there are 20 doses left. If you do not already have a new Easyhaler, contact your doctor for a new prescription. When the counter reaches 0 (zero), you need to replace the Easyhaler. If you use the protective cover, you can keep it and insert your new inhaler into it.
8
Remember •
1. Shake – 2. Click – 3. Inhale.
•
After you have taken the dose, rinse your mouth with water and spit it out and/or brush your teeth.
•
Do not get your inhaler wet, protect it from moisture.
9
……………………………………………………… … Like all medicines, this medicine can cause side effects, although not everybody gets them. If you notice any of the following serious side effects, stop using this medicine and talk to your doctor straight away. You may need urgent medical treatment.
EASYHALER BECLOMETASONE……………………………
……………………… What Easyhaler Beclometasone contains
4
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Orion Pharma UK Ltd, 9th Floor, The Blade, Abbey Square, Reading, RG1 3BE Tel.: +44 1635 520 300 This leaflet was last revised in January 2026 Detailed and updated information on how to use this product is available by scanning this QR code (included also on outer carton and inhaler label) with a smartphone. The same information is also available on the following URL: www.oeh.fi/begb. QR code to www.oeh.fi/begb.
5
How to use the Easyhaler inhaler About your Easyhaler Easyhaler Beclometasone may be different to inhalers you have used in the past. Therefore it is very important that you use it properly as using incorrectly can lead to you not receiving the right amount of medicine. This could make you very unwell or could lead to your asthma not being treated as it should. Your doctor, nurse or pharmacist will show you how to use your inhaler properly. Make sure you understand the correct way to use the inhaler. If you are unsure contact your doctor, nurse or pharmacist. As with all inhalers, caregivers should ensure that children prescribed Easyhaler Beclometasone use correct inhalation technique, as described below. You can also use the instruction video at www.oeh.fi/begb. When you first get your Easyhaler The Easyhaler comes in a foil bag. Do not open the foil bag until you are ready to start using the medicine as it helps to keep the powder dry in the inhaler. When you are ready to start treatment open the bag and record the date e.g., in your calendar. Use the inhaler within 6 months of removing from the foil bag.
Easyhaler Beclometasone 200 micrograms/dose inhalation powder comes as inhaler containing 200mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Easyhaler Beclometasone 200 micrograms/dose inhalation powder is beclometasone dipropionate.
Medicines with the same active substance, strength and form include: Clenil Modulite 200 micrograms inhaler (with Dose Indicator), Clenil Modulite 200 micrograms inhaler (without Dose Indicator), Soprobec 200 micrograms per actuation pressurised inhalation solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Easyhaler Beclometasone 200 micrograms/dose inhalation powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Beclometasone dipropionate given by inhalation offers preventative treatment for asthma. It provides effective anti-inflammatory action in the lungs with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. It also offers preventive treatment of asthma.
Easyhaler® Beclometasone 200 micrograms/dose is indicated in the following:
Adults Prophylactic management in:
Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability):
Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular basis.
Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability):
Patients requiring regular asthma medication and patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.
Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability):
Patients with severe chronic asthma. On transfer to high dose inhaled beclometasone dipropionate, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or eliminate their requirement for oral corticosteroids.
Easyhaler® Beclometasone 200 micrograms/dose is for oral inhalation use only.
Patients should be made aware of the prophylactic nature of therapy with inhaled beclometasone dipropionate and that it should be taken regularly everyday even when they are asymptomatic.
Patients should be given a starting dose of inhaled beclometasone dipropionate appropriate to the severity of their disease. The dose may then be adjusted until control is achieved and should be titrated to the lowest dose at which effective control of asthma is maintained.
Adults
The usual starting dose is 200 micrograms twice a day. In more severe cases the starting dose may need to increase to 600 to 800 micrograms per day which may then be reduced when the patient's asthma has stabilised. The total daily dose may be administered as two, three, or four divided doses.
Paediatric population
Easyhaler® Beclometasone 200 micrograms/dose is not recommended for children.
Special Patient Groups
There is no need to adjust the dose in older people or in those with hepatic or renal impairment.
Hypersensitivity to Beclometasone dipropionate or to the excipients listed in section 6.1 (lactose monohydrate, which contains small amounts of milk proteins).
Special care is necessary in patients with active or quiescent pulmonary tuberculosis.
Patients should be instructed in the proper use of the inhaler, and their technique checked, to ensure that the drug reaches the target areas within the lungs. They should also be made aware that Easyhaler® Beclometasone 200 micrograms/dose has to be used regularly every day for optimum benefit. Patients should be made aware of the prophylactic nature of therapy with Easyhaler® Beclometasone 200 micrograms/dose and that they should be used regularly, even when they are asymptomatic.
Easyhaler® Beclometasone 200 micrograms/dose is not designed to relieve acute asthma symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.
Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death.
Increasing use of bronchodilators, in particular short-acting inhaled beta2 agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.
In this situation, patients should be reassessed and consideration given to the need for increased anti-inflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid) considered. Severe exacerbations of asthma must be treated in the normal way.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Lack of response or severe exacerbations of asthma should be treated by increasing the dose of inhaled beclometasone dipropionate and, if necessary, by giving a systemic steroid and/or antibiotic if there is an infection, and by use of beta-agonist therapy.
For the transfer of patients being treated with oral corticosteroids:
The transfer of oral steroid-dependent patients to Easyhaler® Beclometasone 200 micrograms/dose and their subsequent management needs special care as recovery from impaired adrenocortical function, caused by prolonged systemic steroid therapy, may take a considerable time.
Patients who have been treated with systemic steroids for long periods of time or at a high dose may have adrenocortical suppression. With these patients adrenocortical function should be monitored regularly and their dose of systemic steroid reduced cautiously.
After approximately a week, gradual withdrawal of the systemic steroid is commenced. Decrements in dosages should be appropriate to the level of maintenance systemic steroid, and introduced at not less than weekly intervals. For maintenance doses of prednisolone (or equivalent) of 10mg daily or less, the decrements in dose should not be greater than 1mg per day, at not less than weekly intervals. For maintenance doses of prednisolone in excess of 10mg daily, it may be appropriate to employ cautiously, larger decrements in dose at weekly intervals.
Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of the respiratory function. They should be encouraged to persevere with Easyhaler® Beclometasone 200 micrograms/dose and withdrawal of systemic steroid continued, unless there are objective signs of adrenal insufficiency.
Patients weaned off oral steroids whose adrenocortical function is impaired should carry a steroid warning card indicating that they may need supplementary systemic steroid during periods of stress, e.g. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.
Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.
Treatment with Easyhaler® Beclometasone 200 micrograms/dose should not be stopped abruptly.
As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.
Easyhaler® Beclometasone contains approximately 7mg of lactose per dose. This amount does not normally cause problems in lactose intolerant people. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption should not take this medicine.
Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such agents.
Pregnancy
There is inadequate evidence of safety in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human fetus. It should be noted, however, that the fetal changes in animals occur after relatively high systemic exposure. Easyhaler® Beclometasone 200 micrograms/dose delivers the drug directly to the lungs by the inhaled route and so avoids the high level of exposure that occurs when corticosteroids are given by systemic routes.
The use of beclometasone dipropionate in pregnancy requires that the possible benefits of the drug be weighed against the possible hazards. It should be noted that the drug has been in widespread use for many years without apparent ill consequence.
Breast-feeding
No specific studies examining the transference of beclometasone dipropionate into the milk of lactating animals have been performed. It is reasonable to assume that beclometasone dipropionate is secreted in milk, but at the dosages used for direct inhalation there is low potential for significant levels in breast milk. The use of beclometasone dipropionate in mothers breast feeding their babies requires that the therapeutic benefits of the drug be weighed against the potential hazards to the mother and baby.
No adverse effect has been reported.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and <1/10), uncommon ( 1/1000 and <1/100), rare ( 1/10,000 and <1/1000), very rare (<1/10,000) including isolated reports and not known (cannot be estimated from the available data). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo and comparator group has not been taken into account in estimation of these frequencies. Rare and very rare events were generally determined from spontaneous data.
System Organ Class
Adverse Event
Frequency
Infections & Infestations
Candidiasis of the mouth and throat.
Very Common
Immune System Disorders
Hypersensitivity reactions with the following manifestations:
Rashes, urticaria, pruritis, erythema.
Uncommon
Oedema of the eyes, face, lips and throat
Very Rare
Respiratory symptoms (dyspnoea and/or bronchospasm)
Very Rare
Anaphylactoid/anaphylactic reactions
Very Rare
Endocrine Disorders
Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma
Very Rare
Psychiatric Disorders
Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children)
Not known
Eye disorders
Vision blurred (see also section 4.4)
Not known
Respiratory, Thoracic & Mediastinal Disorders
Hoarseness/throat irritation, cough
Common
Paradoxical bronchospasm
Very Rare
Eosinophilic pneumonia
Not Known
Skin and subcutaneous tissue disorders
Easy bruising, skin thinning
Not known
Candidiasis of the mouth and throat (thrush) occurs in some patients, the incidence increasing with doses greater than 400 micrograms of beclometasone dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Patients may find it helpful to rinse their mouth thoroughly with water after using the inhaler. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with Easyhaler® Beclometasone 200 micrograms/dose treatment.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma (see 4.4 Special Warnings and Precautions for Use).
In some patients inhaled beclometasone dipropionate may cause hoarseness, cough, throat irritation and sore throat. It may be helpful to rinse the mouth out with water immediately after inhalation.
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. The beclometasone dipropionate preparation should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Acute: Inhalation of the drug in doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not require emergency action. In these patients treatment with beclometasone diproprionate by inhalation should be continued at a dose sufficient to control asthma; adrenal function recovers in a few days and can be verified by measuring plasma cortisol.
Chronic: Use of inhaled beclometasone dipropionate in daily doses in excess of 1,500 micrograms over prolonged periods may lead to some degree of adrenal suppression. Monitoring of adrenal reserve may be indicated. Treatment should be continued at a dose sufficient to control asthma.
Ask anything about Easyhaler Beclometasone 200 micrograms/dose inhalation powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.